Sanofi’s MS Drug Gets European Backing Despite US Rejection

Sanofi’s multiple sclerosis medicine tolebrutinib was recommended for approval by European regulators, a boost for the drugmaker after it failed to gain approval for the medicine in the US.

The European Medicines Agency’s human medicines committee endorsed giving marketing authorization for the drug — to be called Cenrifki — to treat a type of multiple sclerosis where the condition steadily worsens without relapses.